Brief: Mabion Gets Permission For Briding Clinical Trial Of MabionCD20 Drug For Rheumatoid Arthritis Patients
11/10/2021 17:31
Oct 11 (Reuters) - Mabion SA MABP.WA :
* SAYS GETS PERMISSION FROM POLAND'S MEDICINES AUTHORITY TO
RUN
BRIDING CLINICAL TRIAL OF MABIONCD20 DRUG FOR RHEUMATOID
ARTHRITIS PATIENTS
Source text for Eikon: ID:nEM7c8XV1a
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects